COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids; LABA, long-acting β₂-agonist; LAMA, long acting muscarinic antagonist; OD, once-daily
TRELEGY Ellipta was developed in collaboration with INNOVIVA Inc.
© 2017 GlaxoSmithKline Group of Companies. TRELEGY and Ellipta are trademarks of the GSK group of companies.
Materials supplied by the above-country business unit to LOCs, for localisation must be subject to local Medical and/or Regulatory review and approval prior to external distribution